Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations

优化含有 MET 外显子 14 突变的肺癌的治疗方法

基本信息

  • 批准号:
    9891979
  • 负责人:
  • 金额:
    $ 44.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-01 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

Lung cancer is the largest cancer killer but is also a heterogeneous disease in which different oncoproteins contribute to genetic subtypes, some of which carry specific treatments. Despite favorable outcomes when therapies are matched to driving oncogenes, only small fraction of lung cancer patients are treated in a targeted manners. Our goal is to optimize targeted therapy for the large proportion of lung cancer patients harboring activating mutations in the Mesenchymal Epithelial Transformation (MET) gene. Background: MET mutations are the most recent addition to the list of druggable, recurrently mutated kinases in nonsmall cell lung cancer (NSCLC). We have recently defined the frequency of MET aberrations in NSCLC, and identified exon 14 deletion in the juxtamembrane domain of MET as the most common somatic MET event. The mechanism for its action and its susceptibility to existing targeted MET therapies is however poorly defined, preventing targeted treatment of this large population of NSCLC patients. Methods: We will focus on the many effects MET exon 14 mutations may have on the kinase, with the goal of understanding how this mutation drives cancer. We will first characterize the juxtamembrane segment of MET regulates the kinase. Next, we will study how exon 14 deletions affect MET inhibitors' binding and whether mutation confers affinity for specific classes of kinase inhibitors. Finally, we will model prototypical resistance mutations to first generation (Type I) MET inhibitors in vivo, and suggest strategies to overcome them using targeted approaches with Type II inhibitors. Impact: This project focuses on a common and understudied mutation in lung cancer, the most lethal cancer type, by far. Thousands of Americans die each year with MET-mutated lung cancer, and often do so without being considered for targeted therapy against their tumor's genotype. We will clarify the role MET mutation plays in lung cancer and will structurally define how the most common mutations activate this oncoprotein. This project will foster development of therapies targeting MET exon 14 mutations, and optimize approaches to targeting the most common anticipated routes of resistance.
肺癌是最大的癌症杀手,但也是一种异质性疾病, 癌蛋白有助于基因亚型,其中一些携带特定的治疗。尽管有利 当治疗与驱动癌基因相匹配时,只有一小部分肺癌患者 以有针对性的方式对待。我们的目标是优化大比例肺癌的靶向治疗 间充质上皮转化(MET)基因中携带激活突变的患者。 背景:MET突变是最近加入到可药物化的、反复突变的激酶列表中的, 非小细胞肺癌(NSCLC)。我们最近确定了NSCLC中MET畸变的频率, 并且鉴定MET的质膜结构域中的外显子14缺失为最常见的体细胞MET事件。 然而,其作用机制及其对现有靶向MET疗法的敏感性尚不明确, 阻止对这一庞大的NSCLC患者群体进行靶向治疗。 方法:我们将关注MET外显子14突变可能对激酶产生的多种影响,目标是 了解这种突变如何导致癌症。我们将首先描述MET的质膜部分, 调节激酶。接下来,我们将研究外显子14缺失如何影响MET抑制剂的结合,以及是否 突变赋予对特定种类的激酶抑制剂的亲和力。最后,我们将模拟原型阻力 突变的第一代(I型)MET抑制剂在体内,并建议策略,以克服他们使用 II型抑制剂的靶向方法。 影响:该项目的重点是肺癌中一种常见且未充分研究的突变,肺癌是最致命的癌症。 类型,到目前为止。每年有成千上万的美国人死于MET突变的肺癌,而且通常没有 正在考虑针对他们的肿瘤基因型进行靶向治疗。我们将阐明MET突变的作用 在肺癌中起作用,并将在结构上定义最常见的突变如何激活这种癌蛋白。 该项目将促进靶向MET外显子14突变的疗法的开发,并优化方法, 针对最常见的预期抵抗路线。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eric Collisson其他文献

Eric Collisson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eric Collisson', 18)}}的其他基金

Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy
利用下一代成像和液体活检优化胰腺癌治疗
  • 批准号:
    10376196
  • 财政年份:
    2021
  • 资助金额:
    $ 44.51万
  • 项目类别:
Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer
了解 1,2,4-三氧戊环在癌症中的功效和 Fe(II) 促进的激活
  • 批准号:
    10374172
  • 财政年份:
    2021
  • 资助金额:
    $ 44.51万
  • 项目类别:
Optimizing Pancreatic Cancer Management with Next Generation Imaging and Liquid Biopsy
利用下一代成像和液体活检优化胰腺癌治疗
  • 批准号:
    10584523
  • 财政年份:
    2021
  • 资助金额:
    $ 44.51万
  • 项目类别:
Understanding Efficacy and Fe(II)-Promoted Activation of 1,2,4-Trioxolanes in Cancer
了解 1,2,4-三氧戊环在癌症中的功效和 Fe(II) 促进的激活
  • 批准号:
    10622460
  • 财政年份:
    2021
  • 资助金额:
    $ 44.51万
  • 项目类别:
The structural and functional basis of MET exon 14 activation and acquired drug resistance
MET 外显子 14 激活和获得性耐药的结构和功能基础
  • 批准号:
    9754544
  • 财政年份:
    2019
  • 资助金额:
    $ 44.51万
  • 项目类别:
The structural and functional basis of MET exon 14 activation and acquired drug resistance
MET 外显子 14 激活和获得性耐药的结构和功能基础
  • 批准号:
    9892984
  • 财政年份:
    2019
  • 资助金额:
    $ 44.51万
  • 项目类别:
The structural and functional basis of MET exon 14 activation and acquired drug resistance
MET 外显子 14 激活和获得性耐药的结构和功能基础
  • 批准号:
    10375379
  • 财政年份:
    2019
  • 资助金额:
    $ 44.51万
  • 项目类别:
Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations
优化含有 MET 外显子 14 突变的肺癌的治疗方法
  • 批准号:
    9763138
  • 财政年份:
    2019
  • 资助金额:
    $ 44.51万
  • 项目类别:
The structural and functional basis of MET exon 14 activation and acquired drug resistance
MET 外显子 14 激活和获得性耐药的结构和功能基础
  • 批准号:
    10580077
  • 财政年份:
    2019
  • 资助金额:
    $ 44.51万
  • 项目类别:
Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations
优化含有 MET 外显子 14 突变的肺癌的治疗方法
  • 批准号:
    10589867
  • 财政年份:
    2019
  • 资助金额:
    $ 44.51万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 44.51万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.51万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 44.51万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.51万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 44.51万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 44.51万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.51万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 44.51万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 44.51万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 44.51万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了